NASDAQ:DERMDermira Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dermira Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.75 0.00 (0.00 %) (As of 02/20/2020) Add Compare Share Today's Range$18.75Now: $18.75▼$18.7550-Day Range$18.73MA: $18.75▼$18.8552-Week Range$5.25Now: $18.75▼$19.48VolumeN/AAverage Volume1.24 million shsMarket Capitalization$1.02 billionP/E RatioN/ADividend YieldN/ABeta1.56 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 1.3 Analyst's Opinion Consensus RatingDermira has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.94, Dermira has a potential downside of 9.7% from its current price of $18.75.Amount of Analyst CoverageDermira has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesDermira has received 342 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDermira has received 309 “underperform” votes. (Add your “underperform” vote.)Community SentimentDermira has received 52.53% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote “Outperform” if you believe DERM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDermira does not currently pay a dividend.Dividend GrowthDermira does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dermira insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.40% of the stock of Dermira is held by insiders.Percentage Held by Institutions98.72% of the stock of Dermira is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Dermira are expected to decrease in the coming year, from ($4.15) to ($4.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dermira is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dermira is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 1.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.97 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DERM Previous Symbol CUSIPN/A CIK1557883 Webwww.dermira.com Phone650-421-7200Debt Debt-to-Equity Ratio25.08 Current Ratio7.03 Quick Ratio6.63Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$42.34 million Price / Sales24.14 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / Book-89.29Profitability EPS (Most Recent Fiscal Year)($5.24) Net Income$-221,540,000.00 Net Margins-256.08% Return on Equity-583.07% Return on Assets-50.25%Miscellaneous Employees333 Outstanding Shares54,520,000Market Cap$1.02 billion Next Earnings DateN/A OptionableOptionable Receive DERM News and Ratings via Email Sign-up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter. Dermira (NASDAQ:DERM) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Dermira? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dermira. How were Dermira's earnings last quarter? Dermira Inc (NASDAQ:DERM) posted its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, topping the consensus estimate of ($1.40) by $0.34. The biopharmaceutical company had revenue of $11.53 million for the quarter, compared to analysts' expectations of $11.07 million. Dermira had a negative return on equity of 583.07% and a negative net margin of 256.08%. View Dermira's earnings history. What price target have analysts set for DERM? 6 equities research analysts have issued twelve-month price targets for Dermira's shares. Their forecasts range from $14.00 to $20.00. On average, they expect Dermira's stock price to reach $16.94 in the next twelve months. This suggests that the stock has a possible downside of 9.7%. View analysts' price targets for Dermira. Has Dermira been receiving favorable news coverage? Media headlines about DERM stock have been trending somewhat negative on Thursday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dermira earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days. View the latest news aboutDermira. Who are some of Dermira's key competitors? Some companies that are related to Dermira include Evotec (EVTCY), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), Biohaven Pharmaceutical (BHVN), GW Pharmaceuticals PLC- (GWPH), ChemoCentryx (CCXI), BridgeBio Pharma (BBIO), Agios Pharmaceuticals (AGIO), Arena Pharmaceuticals (ARNA), Allakos (ALLK), Amicus Therapeutics (FOLD), Arrowhead Pharmaceuticals (ARWR), Deciphera Pharmaceuticals (DCPH) and PTC Therapeutics (PTCT). View all competitors. What other stocks do shareholders of Dermira own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Novavax (NVAX), AT&T (T), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Exelixis (EXEL), ImmunoGen (IMGN) and Karyopharm Therapeutics (KPTI). Who are Dermira's key executives? Dermira's management team includes the following people: Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 67)Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 77)Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 51)Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 42)Mr. Christopher M. Griffith, Co-Founder and Chief Bus. & Strategy Officer (Age 43) What is Dermira's stock symbol? Dermira trades on the NASDAQ under the ticker symbol "DERM." What is Dermira's stock price today? One share of DERM stock can currently be purchased for approximately $18.75. How big of a company is Dermira? Dermira has a market capitalization of $1.02 billion and generates $42.34 million in revenue each year. The biopharmaceutical company earns $-221,540,000.00 in net income (profit) each year or ($5.24) on an earnings per share basis. Dermira employs 333 workers across the globe. What is Dermira's official website? The official website for Dermira is www.dermira.com. How can I contact Dermira? Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
